Meeting
2023 ASCO Annual Meeting
The initial report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors.
Authors
Siqing Fu
Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX
Siqing Fu , Madappa N. Kundranda , Shah Rahimian , Yinan Shen , Qian Tan , Ronghua Zhao , Naghmeh Esmaeili , Manu Singh , Jun Ding , Yanal Murad , Tingbo Liang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
New Targets and New Technologies (IO)
Clinical Trial Registration Number
NCT05266612
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2580)
DOI
10.1200/JCO.2023.41.16_suppl.2580
Abstract #
2580
Poster Bd #
422
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
First-in-human, phase I study of AK109, an anti-VEGFR2 antibody, in patients (pts) with advanced or metastatic solid tumors.
First Author: Nong Xu
Poster
2020 Gastrointestinal Cancers Symposium
Safety, pharmacokinetics, and efficacy of RC48-ADC in a phase I study in patients with HER2-overexpression advanced solid cancer.
First Author: Jifang Gong
Poster
2019 ASCO Annual Meeting
A phase I multiple-dose escalation study to assess the safety, tolerability, and pharmacokinetics of VEGF-receptor inhibitor telatinib (EOC315) in Chinese patients with advanced solid tumors.
First Author: Hongming Pan
Poster
2019 ASCO Annual Meeting
Pooled analysis of phase I dose-escalation and dose cohort expansion studies of IMP4297, a novel PARP inhibitor, in Chinese and Australian patients with advanced solid tumors.
First Author: Junning Cao